Non-invasive enzyme screen for tissue remodeling associated...

Details Non-invasive enzyme screen for tissue remodeling associated... Non-invasive enzyme screen for tissue remodeling associated...

2006-10-23

2008-10-07

Yu, Misook (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

Reexamination Certificate

active

07432066

ABSTRACT:
Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs.

REFERENCES:
patent: 6037138 (2000-03-01), Moses et al.
patent: 6610484 (2003-08-01), Hung
patent: 7153660 (2006-12-01), Moses et al.
patent: 2007/0196876 (2007-08-01), Moses
patent: WO-93/20447 (1993-10-01), None
patent: WO-96/32647 (1996-10-01), None
patent: WO-97/41441 (1997-11-01), None
patent: WO-97/41441 (1997-11-01), None
patent: WO-02/31507 (2002-04-01), None
patent: WO-02/071928 (2002-09-01), None
patent: WO-2004/088276 (2004-10-01), None
Yan et al (Journal of Biological Chemistry, 2001, 276(40): 37258-37265).
Moses et al (Cancer Research, 1998, 58:1395-1399).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Black et al. (Abstract)Clinical Cancer Research, Feb. 2000, vol. 6, pp. 467-473.
Kolkenbrock et al. “Progelatinase B forms from human neutrophils.” complex formation of monomer/lipocalin with TIMP-1,Biol Chem., Jul.-Aug. 1996;377(7-8):529-33.
Stoesz et al. “Heterogeneous expression of the lipocalin NGAL in primary breast cancers,”Int J Cancer, Dec. 18, 1998;79(6):565-72.
Kerr et al.,Immunochemistry Lab Fax, 1994, pp. 115-122.
Tsuda et al. “Isolation and characterization of a high molecular weight type IV collagenase isolated from human carcinoma tissue,”FEBS Lett., Mar. 15, 1993;319(1-2):35-9.
Monier et al (Abstract)Clinica Chimica Acta, Sep. 2000, vol. 299, pp. 11-23.
Kjeldsen et al. “Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase,”J Biol Chem., May 15, 1993;268(14):10425-32.
Baker et al. “Serum metalloproteinases and their inhibitors: markers for malignant potential,”Br J Cancer., Sep. 1994;70(3):506-12.
Garbisa et al. “Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy,”Cancer Res., Aug. 15, 1992;52(16):4548-9.
Kleiner et al. “Matrix metalloproteinases and metastasis,”Cancer Chemother Pharmacol., 1999;43 Suppl:S42-51.
Lochter et al. “The significance of matrix metalloproteinases during early stages of tumor progression,”Ann N Y Acad Sci., Oct. 23, 1998;857:180-93.
Monier et al., “Gelatinase isoforms in urine from bladder cancer patients,”Clin Chim Acta., Sep. 2000;299(1-2):11-23.
Moses et al., “Increased incidence of matrix metalloproteinases in urine of cancer patients,”Cancer Res. Apr. 1, 1998;58(7):1395-9.
Nakajima et al., “Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma,”Cancer Res., Dec. 1, 1993;53(23):5802-7.
Yan et al. “The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modualtion of MMP-9 activity by NGAL,”J Biol Chem., Oct. 5, 2001;276(40):37258-65.
Zucker et al. “Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment,”Ann N Y Acad Sci., Sep. 6, 1994;732:248-62.
“Quantikine—Human Lipocalin-2/NGAL Immunoassay,” Catalog No. DLCN20, pp. 1-15 Retrieved from the Internet on Feb. 2, 2006 at URL: http://www.rndsystems.com/pdf/DLCN20.p.
Bon, et al. “Clinical and technical evaluation of ACS™ BR serum assay of MUCI gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays,”Clinical Chemistry, 43:4, (1997) pp. 585-593.
Fernandez et al. “The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipcalin complex Plays a Role in Breast Tumor Growth and is Present in the Urine of Breast Cancer Patients,”Clinical Cancer Research, vol. 11, No. 15; Aug. 1, 2005; pp. 5390-5395.
Friedl, et al. “Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression,”The Histochemical Journal, vol. 31, No. 7, Jul. 1999, pp. 433-441.
Kjeldsen et al. “Characterization of two ELISAs for NGAL, a newly described lipocalin in human neutroiphils,”Journal of Immunological Methods, 1996 vol. 198 pp. 155-164.
Larue et al. “Epithelial-mesenchymal transition in development and cancer; role of phosphatidylinositol 3′ kinase/AKT pathways”,Oncogene, 2005 vol. 24, pp. 7443-7454.
Mishra et al. “Identification of Neutrophil Gelatinase-Associated Lipocalin as a Novel Early Urinary Biomarker for Ischemic Renal Injury,”J. Am. Soc. Nephrol., 2003 vol. 14, pp. 2534-2543.
Santin et al. “Gene Expression Profiles in Primary Ovarian Serous Papillary Tumors and Normal Ovarian Epithelium: Identification of Candidate Molecular Markers for Ovarian Cancer Diagnosis and Therapy,”Int. J. Cancer, 2004 vol. 112 pp. 14-25.
Skates et al. “Toward an Optimal Algortihm for Ovarian Cancer Screening with Longitudinal Tumor Markers,”Cancer, Nov. 10, 1995; vol. 76, pp. 2004-2010.

Affiliated with

Also associated with

Rating

Non-invasive enzyme screen for tissue remodeling associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non-invasive enzyme screen for tissue remodeling associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-invasive enzyme screen for tissue remodeling associated... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4008877